Opinion|Videos|January 5, 2024
Assessing Treatment Response in Patients With Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Kisqali Plus Aromatase Inhibitor Shows Long-Term Benefit in Early Breast Cancer
2
HR+/HER2- Metastatic Breast Cancer Progression Improved With Sac-TMT
3
Tiragolumab Plus Tecentriq Doesn’t Improve NSCLC Outcomes
4
Keytruda Combo Improves Progression, Survival in Recurrent Ovarian Cancer
5
